The norepinephrine transporter (NET), which modulates the amount of norepinephrine in the synaptic cleft, has been targeted for the treatment of neuropsychiatric disorders exemplified by major depressive disorder (MDD) (Nutt, 2006). The gene discussed is SLC6A2; the disease is major depressive disorder.